Terms: = Ovarian cancer AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954 AND Diagnosis
29 results:
1. Rate of Pathogenic Germline Variants in Patients With Lung cancer.
Sorscher S; LoPiccolo J; Heald B; Chen E; Bristow SL; Michalski ST; Nielsen SM; Lacoste A; Keyder E; Lee H; Nussbaum RL; Martins R; Esplin ED
JCO Precis Oncol; 2023 Sep; 7():e2300190. PubMed ID: 37992258
[TBL] [Abstract] [Full Text] [Related]
2. Access disparities and underutilization of germline genetic testing in Chilean breast cancer patients.
Acevedo F; Walbaum B; Camus M; Manzor M; Muñiz S; Medina L; Petric M; Reyes P; Domínguez F; Puschel K; Merino T; Bravo ML; Pinto MP; Ibáñez C; Hughes K; Sánchez C
Breast Cancer Res Treat; 2023 Jun; 199(2):363-370. PubMed ID: 36988750
[TBL] [Abstract] [Full Text] [Related]
3. Family History of Prostate cancer and Survival Outcomes in the UK Genetic Prostate cancer Study.
Brook MN; Ní Raghallaigh H; Govindasami K; Dadaev T; Rageevakumar R; Keating D; Hussain N; Osborne A; Lophatananon A; ; Muir KR; Kote-Jarai Z; Eeles RA
Eur Urol; 2023 Mar; 83(3):257-266. PubMed ID: 36528478
[TBL] [Abstract] [Full Text] [Related]
4. Evaluation of family history in individuals with heterozygous BRCA pathogenic variants diagnosed with breast or ovarian cancer in a single center in Italy.
Negri S; De Ponti E; Sina FP; Sala E; Dell'Oro C; Roversi G; Lazzarin S; Delle Marchette M; Inzoli A; Toso C; Fumagalli S; Campanella M; Kotsopoulos J; Fruscio R
Mol Genet Genomic Med; 2022 Dec; 10(12):e2071. PubMed ID: 36307994
[TBL] [Abstract] [Full Text] [Related]
5. Significance of prostate/pancreatic/skin cancer family history for detecting BRCA2 pathogenic variant careers among patients with breast cancer.
Minoura Y; Takahashi M; Maeda H; Kuwahara S; Tachikawa H; Yamamoto M; Tomioka N; Watanabe K; Sakurai A
Breast Cancer; 2022 Sep; 29(5):808-813. PubMed ID: 35641852
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors.
Lee A; Yang X; Tyrer J; Gentry-Maharaj A; Ryan A; Mavaddat N; Cunningham AP; Carver T; Archer S; Leslie G; Kalsi J; Gaba F; Manchanda R; Gayther S; Ramus SJ; Walter FM; Tischkowitz M; Jacobs I; Menon U; Easton DF; Pharoah P; Antoniou AC
J Med Genet; 2022 Jul; 59(7):632-643. PubMed ID: 34844974
[TBL] [Abstract] [Full Text] [Related]
7. Identification of women at risk of hereditary breast-ovarian cancer among participants in a population-based breast cancer screening.
Bonelli L; Valle I; Rebora I; Ricci P; Biocchi L; Bruschi G; Parodi S; Bruzzone C; Varesco L
Fam Cancer; 2022 Jul; 21(3):309-318. PubMed ID: 34669096
[TBL] [Abstract] [Full Text] [Related]
8. Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.
Sabol RA; Ledet EM; Jaeger E; Hatton W; Moses M; Lankford A; Zaheria A; Barata P; Layton JL; Lewis BE; Sartor O
Prostate; 2021 May; 81(7):427-432. PubMed ID: 33760238
[TBL] [Abstract] [Full Text] [Related]
9. Revisiting the Genomic and Transcriptomic Landscapes from Female Malignancies Could Provide Molecular Markers and Targets for Precision Medicine.
Taniguchi-Ponciano K; Huerta-Padilla V; Baeza-Xochihua V; Ponce-Navarrete G; Salcedo E; Gomez-Apo E; Chavez-Macias L; Aviles-Duran J; Ruiz-Sanchez H; Valdivia A; Peralta R; Romero-Anduaga H; Rosas-Vargas H; Quijano F; Salcedo M; Marrero-Rodríguez D
Arch Med Res; 2019 Oct; 50(7):428-436. PubMed ID: 31783305
[TBL] [Abstract] [Full Text] [Related]
10. Differential Profile of BRCA1 vs. BRCA2 Mutated Families: A Characterization of the Main Differences and Similarities in Patients.
Fernandes GC; Felicio PS; Michelli RAD; Coelho AS; Scapulatempo-Neto C; Palmero EI
Asian Pac J Cancer Prev; 2019 Jun; 20(6):1655-1660. PubMed ID: 31244284
[TBL] [Abstract] [Full Text] [Related]
11. BRCA mutation testing for ovarian cancer in the context of available targeted therapy: Survey and consensus of Hong Kong specialists.
Kwong A; Cheng KD; Hsue CV; Hui SK; Leung CR; Leung KA; Ngan KR; Soong SI
Asia Pac J Clin Oncol; 2019 Mar; 15 Suppl 2():20-31. PubMed ID: 30838787
[TBL] [Abstract] [Full Text] [Related]
12. Psychological outcomes and surgical decisions after genetic testing in women newly diagnosed with breast cancer with and without a family history.
Meiser B; Quinn VF; Mitchell G; Tucker K; Watts KJ; Rahman B; Peate M; Saunders C; Geelhoed E; Gleeson M; Barlow-Stewart K; Field M; Harris M; Antill YC; Susman R; Bowen MT; Mills L; Kirk J;
Eur J Hum Genet; 2018 Jul; 26(7):972-983. PubMed ID: 29599518
[TBL] [Abstract] [Full Text] [Related]
13. Management of Undifferentiated Solitary Mucinous Cystic Lesion of the Pancreas: A Clinical Dilemma.
Roch AM; Bigelow K; Schmidt CM; Carr RA; Jester AL; Ceppa EP; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
J Am Coll Surg; 2017 Apr; 224(4):717-723. PubMed ID: 28126546
[TBL] [Abstract] [Full Text] [Related]
14. Hereditary non-BRCA gynecological tumors.
Vellone VG; Paudice M; Varesco L
Minerva Ginecol; 2016 Oct; 68(5):579-86. PubMed ID: 26930387
[TBL] [Abstract] [Full Text] [Related]
15. BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer.
El Saghir NS; Zgheib NK; Assi HA; Khoury KE; Bidet Y; Jaber SM; Charara RN; Farhat RA; Kreidieh FY; Decousus S; Romero P; Nemer GM; Salem Z; Shamseddine A; Tfayli A; Abbas J; Jamali F; Seoud M; Armstrong DK; Bignon YJ; Uhrhammer N
Oncologist; 2015 Apr; 20(4):357-64. PubMed ID: 25777348
[TBL] [Abstract] [Full Text] [Related]
16. Aligning policy to promote cascade genetic screening for prevention and early diagnosis of heritable diseases.
George R; Kovak K; Cox SL
J Genet Couns; 2015 Jun; 24(3):388-99. PubMed ID: 25577298
[TBL] [Abstract] [Full Text] [Related]
17. OVA12, a novel tumor antigen, promotes cancer cell growth and inhibits 5-fluorouracil-induced apoptosis.
Zhang R; Jin S; Rao W; Song F; Yin Q; Wang Y; Wang L; Xi Y; Zhang X; Wang M; Ge H
Cancer Lett; 2015 Feb; 357(1):141-151. PubMed ID: 25444895
[TBL] [Abstract] [Full Text] [Related]
18. Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less.
Bayraktar S; Amendola L; Gutierrez-Barrera AM; Hashmi SS; Amos C; Gambello M; Ready KJ; Arun B
Breast; 2014 Dec; 23(6):770-4. PubMed ID: 25231195
[TBL] [Abstract] [Full Text] [Related]
19. BAG3 upregulates mcl-1 through downregulation of miR-29b to induce anticancer drug resistance in ovarian cancer.
Sugio A; Iwasaki M; Habata S; Mariya T; Suzuki M; Osogami H; Tamate M; Tanaka R; Saito T
Gynecol Oncol; 2014 Sep; 134(3):615-23. PubMed ID: 24992675
[TBL] [Abstract] [Full Text] [Related]
20. Family history of cancer and the risk of cancer: a network of case-control studies.
Turati F; Edefonti V; Bosetti C; Ferraroni M; Malvezzi M; Franceschi S; Talamini R; Montella M; Levi F; Dal Maso L; Serraino D; Polesel J; Negri E; Decarli A; La Vecchia C
Ann Oncol; 2013 Oct; 24(10):2651-2656. PubMed ID: 23884440
[TBL] [Abstract] [Full Text] [Related]
[Next]
